Navonil DS
@Navonilde
Followers
384
Following
2K
Media
89
Statuses
739
(Pronouns He/Him). DAD/Husband/Scientist @ProstateCancer @CancerGenomics @Biomarker_Research @Mountain_Lover @DNA repair @Signature 'tweet are mine'
Seattle, WA
Joined May 2009
Excited to release my lab's first preprint! A foundational model for clone & epistasis-aware biomarkers. This approach addresses key challenges in understanding genetic interactions & clonal dynamics. Looking forward to feedback & new collaborations!
biorxiv.org
Current DNA damage repair (DDR) biomarkers employ binary classifications that fail to capture the molecular complexity of tumors with concurrent repair deficiencies. We used genomics analysis to...
1
0
3
Truly Honored and grateful for the The PCF Foundation Medicine Collaborative Research Award. I missed you @deepak_kilari at the award ceremony. @MCWCancerCenter @mcwpathology @McwPharmTox
1
0
12
Highlight of my year...Pact with exciting science. Thanks @PCF_Science
The 32nd Annual #PCFRetreat25 brought together the brightest minds in #ProstateCancer research to discuss groundbreaking science, collaboration and innovation. Here's to continued breakthroughs in research ahead. #Research #Innovation #ThinkTank
0
0
4
The 32nd Annual #PCFRetreat25 brought together the brightest minds in #ProstateCancer research to discuss groundbreaking science, collaboration and innovation. Here's to continued breakthroughs in research ahead. #Research #Innovation #ThinkTank
1
17
53
"The energy, the science, the medicine. It's so rich." @soulehoward1, PhD, EVP & Chief Science Officer recaps the 32nd Annual PCF Scientific Retreat. #PCFRetreat25
1
6
10
See you all at the @PCF_Science AnnualRetreat! Stop by our poster: "Machine Learning based Detection of Concurrent DNA Repair Deficiencies as Dynamic Biomarkers for Prostate Cancer Precision Medicine" Discuss approach, hear your thoughts! Collab #ProstateCancer #PrecisionMedicine
2
1
0
Outstanding discussion by @AzadOncology on #PSMAaddition at #ESMO25 👉highlighting the need for a personalized approach in mHSPC #ProstateCancer 👉 pt selection, toxicity vigilance, & that not all pts need Lu-177 or 6 cycles 👉precision, not over-treatment. @OncoAlert @UroToday
1
32
59
Great Keynote address by Nobel Laureate Prof. William Kaelin speaking on Drugging the Undruggable at the #APM Advancing Precision Medicine meeting #Philadelphia . Privileged to be here as a faculty @WIN_Consortium @weldeiry @Dr_R_Kurzrock #PrecisionOncology
Excited to welcome Nobel Laureate Dr. William G. Kaelin, Jr, Opening Keynote Speaker at our upcoming #win2025, in collaboration with @AdvPrecMed 3-4 October 2025. With leading experts from @AACR amongst others. Register now! https://t.co/65d0V9DxD1
1
9
17
The hardest lessons after training aren’t always in the OR or clinic. 🙏 I wrote this essay for anyone navigating their first year as an attending. “Unseen Scars” in @JAMA_current 🔗 https://t.co/0e09Zx1nb6
54
165
685
Definitely worth a read
The hardest lessons after training aren’t always in the OR or clinic. 🙏 I wrote this essay for anyone navigating their first year as an attending. “Unseen Scars” in @JAMA_current 🔗 https://t.co/0e09Zx1nb6
0
3
15
🚨 It’s not just a number—it’s a wake-up call! 🚨 This #ProstateCancerAwarenessMonth, the UCF and the @PCFnews are teaming up to spotlight the urgent need for early detection, especially in communities at higher risk. Access FREE resources 👉 https://t.co/emQWKGnuJU
0
3
6
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers: Cancer Cell
cell.com
Feng et al. demonstrate the potent antitumor efficacy of MCB-294, a pan-KRAS inhibitor, and MCB-36, a derivative proteolysis-targeting chimera (PROTAC) degrader. MCB-294 engages both active and...
0
4
26
Now online in @CD_AACR: Eradicating Drug Tolerant Persister Cells in EGFR-Mutated NSCLC by Targeting TROP2 with CAR-T Cellular Therapy - by Simon Baldacci, @EJBrea, Francesco Facchinetti, @ESmithMDPhD, Pasi Jänne, @DavidBarbie8, and colleagues https://t.co/psE0fK7kPz
@DanaFarber
3
31
107
REGISTER for this FREE exciting @pros_tic @PCFnews Theranostics webinar to hear about the latest clinical trials, experience and translational research from world leaders using Terbium-161! ⬇️
Augerlicious: Terbium-161 Double Punch to Cancer Cells Live & free webinar, register: https://t.co/xj4ElcTLHK Sep 18 or 17 (check your time-zone) Is Terbium-161 superior to Lutetium-177? You'll hear about the latest clinical trials, experience and translational research from
0
3
4
4/ MDT+cADT met the primary endpoint, with median PFS of 47 mo vs 22 with cADT alone.
2
7
20
HOXD13 knockdown attenuates apoptosis in prostate cancer via the upregulation of MDM2/p53 signaling https://t.co/wEZaGDxfKq This study explored the role of HOXD13, a member of the HOX gene family, in #ProstateCancer (PCa), revealing that its expression is significantly reduced
4
6
13